Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
DF Capital builds relationships with manufacturers and provides working capital solutions up and down supply chains.
An operating system for modern psychotherapy - combining care structures and technology within regulated healthcare for better results.
Engimmune Therapeutics is a platform and product development company engineering next-generation T cell receptor therapies.
Wiredirect is a global financial technology and FX liquidity firm that facilitates payments across borders.
Planetly is building the software to analyze, reduce and offset your carbon footprint.
Eirion Therapeutics is a clinical-stage biopharmaceutical company that is developing next-generation prescription products.
Herophilus is a neurotherapeutics discovery company based on next-generation scaled complex in vitro models.
Calyxha is developing novel therapies targeting tissue degeneration that is the fundamental underlying cause of major human diseases.
Yonder helps users find relevant information by providing shorter documents and manageable revisions.
EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine.
NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke,
Yofumo makes cannabis better. From the moment a flower comes off the stalk
Public is a venture capital firm that supports technology startups aiming to work more deeply with the UK’s public services.
WAGZ is a consumer electronics company that provides devices to help pet owners understand, manage, and track furry friends at home.
UV Light Care is a medtech company .
Kinled Holding has invested in 39 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Kinled Holding's top investment sectors include Biotechnology, Financial Services, Therapeutics, Life Science, Venture Capital. The firm invests across 33 different industry categories.
Among tracked funding rounds, Eirion Therapeutics received $40.0M in a Series A round. Kinled Holding's total known invested capital is $2.3B.
Kinled Holding's average investment size is $54.0M across its portfolio of 39 companies.
Recent Kinled Holding portfolio additions include DF Capital, Sympatient, Engimmune Therapeutics, Wiredirect, Planetly. These companies were founded in 2020 or later.